Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Acute Myeloid Leukemia | Research

A chest CT-based nomogram for predicting survival in acute myeloid leukemia

Authors: Xiaoping Yi, Huien Zhan, Jun Lyu, Juan Du, Min Dai, Min Zhao, Yu Zhang, Cheng Zhou, Xin Xu, Yi Fan, Lin Li, Baoxia Dong, Xinya Jiang, Zeyu Xiao, Jihao Zhou, Minyi Zhao, Jian Zhang, Yan Fu, Tingting Chen, Yang Xu, Jie Tian, Qifa Liu, Hui Zeng

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

The identification of survival predictors is crucial for early intervention to improve outcome in acute myeloid leukemia (AML). This study aim to identify chest computed tomography (CT)-derived features to predict prognosis for acute myeloid leukemia (AML).

Methods

952 patients with pathologically-confirmed AML were retrospectively enrolled between 2010 and 2020. CT-derived features (including body composition and subcutaneous fat features), were obtained from the initial chest CT images and were used to build models to predict the prognosis. A CT-derived MSF nomogram was constructed using multivariate Cox regression incorporating CT-based features. The performance of the prediction models was assessed with discrimination, calibration, decision curves and improvements.

Results

Three CT-derived features, including myosarcopenia, spleen_CTV, and SF_CTV (MSF) were identified as the independent predictors for prognosis in AML (P < 0.01). A CT-MSF nomogram showed a performance with AUCs of 0.717, 0.794, 0.796 and 0.792 for predicting the 1-, 2-, 3-, and 5-year overall survival (OS) probabilities in the validation cohort, which were significantly higher than the ELN risk model. Moreover, a new MSN stratification system (MSF nomogram plus ELN risk model) could stratify patients into new high, intermediate and low risk group. Patients with high MSN risk may benefit from intensive treatment (P = 0.0011).

Conclusions

In summary, the chest CT-MSF nomogram, integrating myosarcopenia, spleen_CTV, and SF_CTV features, could be used to predict prognosis of AML.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wang M, Lindberg J, Klevebring D, Nilsson C, Mer AS, Rantalainen M, Lehmann S, Gronberg H. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia. 2017;31(10):2029–36.CrossRefPubMedPubMedCentral Wang M, Lindberg J, Klevebring D, Nilsson C, Mer AS, Rantalainen M, Lehmann S, Gronberg H. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia. 2017;31(10):2029–36.CrossRefPubMedPubMedCentral
2.
go back to reference Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2014;32(15):1586–94.CrossRefPubMedPubMedCentral Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2014;32(15):1586–94.CrossRefPubMedPubMedCentral
3.
go back to reference Itzykson R, Fournier E, Berthon C, Rollig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507–19.CrossRefPubMed Itzykson R, Fournier E, Berthon C, Rollig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507–19.CrossRefPubMed
4.
go back to reference Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, et al. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol. 2022;97(11):E408–11.CrossRefPubMed Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, et al. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol. 2022;97(11):E408–11.CrossRefPubMed
5.
go back to reference Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47.CrossRefPubMed Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47.CrossRefPubMed
6.
go back to reference Nakamura N, Ninomiya S, Matsumoto T, Nakamura H, Kitagawa J, Shiraki M, Hara T, Shimizu M, Tsurumi H. Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia. Ann Hematol. 2019;98(2):351–9.CrossRefPubMed Nakamura N, Ninomiya S, Matsumoto T, Nakamura H, Kitagawa J, Shiraki M, Hara T, Shimizu M, Tsurumi H. Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia. Ann Hematol. 2019;98(2):351–9.CrossRefPubMed
7.
go back to reference Jung J, Lee E, Shim H, Park JH, Eom HS, Lee H. Prediction of clinical outcomes through assessment of Sarcopenia and Adipopenia using computed tomography in adult patients with acute myeloid leukemia. Int J Hematol. 2021;114(1):44–52.CrossRefPubMed Jung J, Lee E, Shim H, Park JH, Eom HS, Lee H. Prediction of clinical outcomes through assessment of Sarcopenia and Adipopenia using computed tomography in adult patients with acute myeloid leukemia. Int J Hematol. 2021;114(1):44–52.CrossRefPubMed
8.
go back to reference Sun Q, Cui J, Liu W, Li J, Hong M, Qian S. The Prognostic Value of Sarcopenia in Acute myeloid leukemia patients and the development and validation of a Novel Nomogram for Predicting Survival. Front Oncol. 2022;12:828939.CrossRefPubMedPubMedCentral Sun Q, Cui J, Liu W, Li J, Hong M, Qian S. The Prognostic Value of Sarcopenia in Acute myeloid leukemia patients and the development and validation of a Novel Nomogram for Predicting Survival. Front Oncol. 2022;12:828939.CrossRefPubMedPubMedCentral
9.
go back to reference Suzuki D, Kobayashi R, Sano H, Hori D, Kobayashi K. Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance. Int J Hematol. 2018;107(4):486–9.CrossRefPubMed Suzuki D, Kobayashi R, Sano H, Hori D, Kobayashi K. Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance. Int J Hematol. 2018;107(4):486–9.CrossRefPubMed
10.
go back to reference Yi X, Chen Q, Yang J, Jiang D, Zhu L, Liu H, Pang P, Zeng F, Chen C, Gong G, et al. CT-Based Sarcopenic Nomogram for Predicting Progressive Disease in Advanced Non-small-cell Lung Cancer. Front Oncol. 2021;11:643941.CrossRefPubMedPubMedCentral Yi X, Chen Q, Yang J, Jiang D, Zhu L, Liu H, Pang P, Zeng F, Chen C, Gong G, et al. CT-Based Sarcopenic Nomogram for Predicting Progressive Disease in Advanced Non-small-cell Lung Cancer. Front Oncol. 2021;11:643941.CrossRefPubMedPubMedCentral
11.
go back to reference Xu F, Zhang L, Wang Z, Han D, Li C, Zheng S, Yin H, Lyu J. A New Scoring System for Predicting In-hospital death in patients having liver cirrhosis with esophageal varices. Front Med (Lausanne). 2021;8:678646.CrossRefPubMed Xu F, Zhang L, Wang Z, Han D, Li C, Zheng S, Yin H, Lyu J. A New Scoring System for Predicting In-hospital death in patients having liver cirrhosis with esophageal varices. Front Med (Lausanne). 2021;8:678646.CrossRefPubMed
12.
go back to reference Li C, Yang J, Xu F, Han D, Zheng S, Kaaya RE, Wang S, Lyu J. A prognostic nomogram for the cancer-specific survival of patients with upper-tract urothelial carcinoma based on the Surveillance, Epidemiology, and end results database. BMC Cancer. 2020;20(1):534.CrossRefPubMedPubMedCentral Li C, Yang J, Xu F, Han D, Zheng S, Kaaya RE, Wang S, Lyu J. A prognostic nomogram for the cancer-specific survival of patients with upper-tract urothelial carcinoma based on the Surveillance, Epidemiology, and end results database. BMC Cancer. 2020;20(1):534.CrossRefPubMedPubMedCentral
13.
go back to reference Seban RD, Rouzier R, Latouche A, Deleval N, Guinebretiere JM, Buvat I, Bidard FC, Champion L. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. Eur J Nucl Med Mol Imaging. 2021;48(11):3560–70.CrossRefPubMed Seban RD, Rouzier R, Latouche A, Deleval N, Guinebretiere JM, Buvat I, Bidard FC, Champion L. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. Eur J Nucl Med Mol Imaging. 2021;48(11):3560–70.CrossRefPubMed
14.
go back to reference Vucinic V, Ruhnke L, Sockel K, Rohnert MA, Backhaus D, Brauer D, Franke GN, Niederwieser D, Bornhauser M, Rollig C, et al. The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia. Blood Adv. 2021;5(24):5584–7.CrossRefPubMedPubMedCentral Vucinic V, Ruhnke L, Sockel K, Rohnert MA, Backhaus D, Brauer D, Franke GN, Niederwieser D, Bornhauser M, Rollig C, et al. The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia. Blood Adv. 2021;5(24):5584–7.CrossRefPubMedPubMedCentral
15.
go back to reference Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86–105.CrossRefPubMed Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86–105.CrossRefPubMed
16.
go back to reference Pabst T, Kortz L, Fiedler GM, Ceglarek U, Idle JR, Beyoglu D. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clin. 2017;7:105–14.CrossRefPubMedPubMedCentral Pabst T, Kortz L, Fiedler GM, Ceglarek U, Idle JR, Beyoglu D. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clin. 2017;7:105–14.CrossRefPubMedPubMedCentral
17.
go back to reference Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, et al. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Oncotarget. 2015;6(29):26909–21.CrossRefPubMedPubMedCentral Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, et al. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Oncotarget. 2015;6(29):26909–21.CrossRefPubMedPubMedCentral
18.
go back to reference van Besien H, Sassano A, Altman JK, Platanias LC. Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Leuk Lymphoma. 2013;54(12):2601–5.CrossRefPubMed van Besien H, Sassano A, Altman JK, Platanias LC. Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Leuk Lymphoma. 2013;54(12):2601–5.CrossRefPubMed
Metadata
Title
A chest CT-based nomogram for predicting survival in acute myeloid leukemia
Authors
Xiaoping Yi
Huien Zhan
Jun Lyu
Juan Du
Min Dai
Min Zhao
Yu Zhang
Cheng Zhou
Xin Xu
Yi Fan
Lin Li
Baoxia Dong
Xinya Jiang
Zeyu Xiao
Jihao Zhou
Minyi Zhao
Jian Zhang
Yan Fu
Tingting Chen
Yang Xu
Jie Tian
Qifa Liu
Hui Zeng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12188-8

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine